文献类型：期刊文献

英文题名：Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling

作者：Zhang, Jing-Jing[1,2];Ye, Xue-Rui[1,2];Liu, Xue-Song[3];Zhang, Hao-Ling[4];Qiao, Qian[1,2]

第一作者：Zhang, Jing-Jing

通信作者：Qiao, Q[1];Zhang, HL[2]

机构：[1]Chinese Acad Med Sci, Fuwai Yunnan Hosp, 528 Shahe North Rd, Kunming 650000, Yunnan, Peoples R China;[2]Kunming Med Univ, Affiliated Cardiovasc Hosp, Kunming 650000, Yunnan, Peoples R China;[3]Gansu Univ Chinese Med, Dept Biochem, Lanzhou 730000, Gansu, Peoples R China;[4]Univ Sains Malaysia, Adv Med & Dent Inst, Dept Biomed Sci, George Town 13200, Malaysia

第一机构：Chinese Acad Med Sci, Fuwai Yunnan Hosp, 528 Shahe North Rd, Kunming 650000, Yunnan, Peoples R China

通信机构：[1]corresponding author), Chinese Acad Med Sci, Fuwai Yunnan Hosp, 528 Shahe North Rd, Kunming 650000, Yunnan, Peoples R China;[2]corresponding author), Univ Sains Malaysia, Adv Med & Dent Inst, Dept Biomed Sci, George Town 13200, Malaysia.

年份：2025

卷号：17

期号：1

外文期刊名：WORLD JOURNAL OF CARDIOLOGY

收录：Scopus(收录号：2-s2.0-85215691080);WOS:【ESCI(收录号:WOS:001413493600002)】；

基金：Supported by Science and Technology Department of Yunnan Province - Kunming Medical University, Kunming Medical Joint Special Project - Surface Project, No. 202401AY070001-164; Yunnan Provincial Clinical Research Center Cardiovascular Diseases - New Technology Research for Development Project for Diagnosis and Treatment Cardiovascular Diseases, No. 202102AA310002; and the Key Technology Research and Device Development Project for Innovative Diagnosis and Treatment of Structural Heart Disease in the Southwest Plateau Region, No. 202302AA310045.

语种：英文

外文关键词：Sodium-glucose cotransporter-2 inhibitors; Pulmonary vascular endothelial cells; Pulmonary vascular smooth muscle cells; Pulmonary artery remodeling; Right heart dysfunction; Cardiovascular disease

摘要：Sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent a cutting-edge class of oral antidiabetic therapeutics that operate through selective inhibition of glucose reabsorption in proximal renal tubules, consequently augmenting urinary glucose excretion and attenuating blood glucose levels. Extensive clinical investigations have demonstrated their profound cardiovascular efficacy. Parallel basic science research has elucidated the mechanistic pathways through which diverse SGLT-2 inhibitors beneficially modulate pulmonary vascular cells and arterial remodeling. Specifically, these inhibitors exhibit promising potential in enhancing pulmonary vascular endothelial cell function, suppressing pulmonary smooth muscle cell proliferation and migration, reversing pulmonary arterial remodeling, and maintaining hemodynamic equilibrium. This comprehensive review synthesizes current literature to delineate the mechanisms by which SGLT-2 inhibitors enhance pulmonary vascular cell function and reverse pulmonary remodeling, thereby offering novel therapeutic perspectives for pulmonary vascular diseases.